Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Liabilities (2020 - 2025)

Candel Therapeutics' Total Liabilities history spans 4 years, with the latest figure at $28.5 million for Q4 2023.

  • On a quarterly basis, Total Liabilities fell 5.07% to $28.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $28.5 million, a 5.07% decrease, with the full-year FY2023 number at $28.5 million, down 5.07% from a year prior.
  • Total Liabilities hit $28.5 million in Q4 2023 for Candel Therapeutics, up from $27.0 million in the prior quarter.
  • Over the last five years, Total Liabilities for CADL hit a ceiling of $37.8 million in Q1 2022 and a floor of $12.3 million in Q2 2020.
  • Historically, Total Liabilities has averaged $26.3 million across 4 years, with a median of $27.6 million in 2023.
  • Biggest five-year swings in Total Liabilities: skyrocketed 122.55% in 2021 and later decreased 27.02% in 2023.
  • Tracing CADL's Total Liabilities over 4 years: stood at $12.8 million in 2020, then soared by 96.09% to $25.1 million in 2021, then rose by 19.58% to $30.0 million in 2022, then fell by 5.07% to $28.5 million in 2023.
  • Business Quant data shows Total Liabilities for CADL at $28.5 million in Q4 2023, $27.0 million in Q3 2023, and $27.9 million in Q2 2023.